--- schema_version: "secwatch.filing_event.v1" accession: "0001493152-24-002896" form_type: "8-K" ticker: "CTOR" cik: "0001851484" company_name: "CITIUS ONCOLOGY, INC." filed_at: "2024-01-18T23:59:59+00:00" generated_at: "2026-06-06T22:06:15.624484+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.6 calibrated_materiality_score: 0.6 confidence: "high" source: SEC EDGAR --- # TenX Keane shareholders OK extension to Nov 18, 2024; $24.9M redeemed ## Summary - Shareholders approved amendment to extend combination deadline from Jan 18, 2024 to Nov 18, 2024 via up to 8 monthly extensions. - Sponsor/Citius Pharma deposited $200k into trust for the first 3-month extension to April 18, 2024. - 2,287,923 ordinary shares redeemed at ~$10.90/share, removing $24.9M from trust account. - Company issued $200k non-interest promissory note to Citius Pharma; due at merger close if trust balance ≥ $2M. - Ratification of Marcum LLP as independent auditor for FY 2023 approved unanimously. ## SEC filing metadata - accession: 0001493152-24-002896 - form_type: 8-K - ticker: CTOR - cik: 0001851484 - company_name: CITIUS ONCOLOGY, INC. - filed_at: 2024-01-18T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.6 - calibrated_materiality_score: 0.6 - confidence: high - sec_items: 1.01, 2.03, 5.03, 5.07, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000149315224002896/0001493152-24-002896-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000149315224002896/form8-k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001493152-24-002896 - JSON: https://secwatch.observer/filing/0001493152-24-002896.json - Plain text: https://secwatch.observer/filing/0001493152-24-002896.txt ## Key facts - Debt Financings CITIUS ONCOLOGY, INC. incurred loan of $200,000 with Citius Pharma at no interest maturing repayable in full per the terms of the Merger Agreement. - Instrument: loan - Principal: $200,000 - Counterparty: Citius Pharma - Rate: no interest - Maturity: repayable in full per the terms of the Merger Agreement - Event: incurrence source text: the Company issued a promissory note to Citius Pharma with a principal amount of $200,000 (the “ Note ”). The Note bears no interest and is repayable in full per the terms of the Merger Agreement. evidence_url: https://www.sec.gov/Archives/edgar/data/1851484/000149315224002896/0001493152-24-002896-index.htm - Governance Changes CITIUS ONCOLOGY, INC.: Shareholders approved amendment to Amended and Restated Memorandum and Articles of Association to extend the combination period in up to eight installments, from January 2024 to November 2024 (effective 2024-01-17). - Change: charter amendment - Effective: 2024-01-17 source text: On January 17, 2024, the Company held the Meeting, in lieu of the 2023 annual general meeting, at which the Company’s shareholders approved (i) a proposal, by special resolution, to amend the Company’s Amended and Restated Memorandum and Articles of Association in their entirety and the substitution in their place of the third amended and restated memorandum and articles of association of the Company (the “ Third A&R Memorandum and Articles ”), which provides that the Company may elect to extend the date by which the Company has to consummate a business combination (the “ Combination Period ”) for a total of eight (8) times, as follow: (a) one (1) time for an additional three (3) months from January 18, 2024 to April 18, 2024, and subsequently (b) seven (7) times for an additional one (1) month each time from April 18, 2024 to November 18, 2024, if requested by the Sponsor and upon two calendar days’ advance notice prior to the applicable deadline evidence_url: https://www.sec.gov/Archives/edgar/data/1851484/000149315224002896/0001493152-24-002896-index.htm - Material Agreements CITIUS ONCOLOGY, INC. entered into Promissory Note with Citius Pharmaceuticals, Inc. valued at 200,000 (effective 2024-01-17). - Action: entry - Counterparty: Citius Pharmaceuticals, Inc. - Value: 200,000 - Effective: 2024-01-17 source text: ub ”), Citius Pharmaceuticals, Inc., a Nevada corporation (“ Citius Pharma ”), and Citius Oncology, Inc., a Delaware corporation and wholly owned subsidiary of Citius Pharma (“ Citius Oncology ”), to acquire Citius Oncology. evidence_url: https://www.sec.gov/Archives/edgar/data/1851484/000149315224002896/0001493152-24-002896-index.htm - Shareholder Votes CITIUS ONCOLOGY, INC. shareholders approved Extension Amendment Proposal. - Proposal: charter amendment - Outcome: passed source text: The shareholders approved the Extension Amendment Proposal and the Auditor Ratification Proposal. evidence_url: https://www.sec.gov/Archives/edgar/data/1851484/000149315224002896/0001493152-24-002896-index.htm - Shareholder Votes CITIUS ONCOLOGY, INC. shareholders approved Auditor Ratification Proposal. - Proposal: auditor ratification - Outcome: passed source text: The shareholders approved the Extension Amendment Proposal and the Auditor Ratification Proposal. evidence_url: https://www.sec.gov/Archives/edgar/data/1851484/000149315224002896/0001493152-24-002896-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.